Abstract：Objective To observe the curative effect and adverse reaction of aprepitant in alleviating nausea and vomiting caused by chemotherapy. Methods 80 patients with cisplatin chemotherapy were randomly divided into study group and control group. The study group used aprepitant combined with the ondansetron hydrochloride, dexamethasone. The control group received palonosetron hydrochlorid combined with ondansetron hydrochloride, and dexamethasone. The curative effect and adverse reactions in the two groups were observed. Results In the study group, complete remission rate and nausea vomiting control rates were 80% and 77.5% respectively, compared with 47.5% and 37.5% in the control group, there was statistically significant difference (P＜0.01). In the two groups, the most adverse reactions mainly included constipation, diarrhea, hiccups, anorexia, fatigue, insomnia, transaminase and elevation, were mild. Conclusions Aprepitant has obvious preventive effect on chemotherapy induced nausea and vomiting, and has clinical application prospects.
苏丹, 赵水喜, 曹京旭. 阿瑞匹坦预防化疗引起恶心呕吐的疗效及安全性[J]. 武警医学, 2016, 27(9): 871-873.
SU Dan, ZHAO Shuixi, and CAO Jingxu. Efficacy and safety of aprepitant in patients with nausea and vomiting caused by chemotherapy. Med. J. Chin. Peop. Armed Poli. Forc., 2016, 27(9): 871-873.
Ettinger D S,Bierman P J,Bradbury B, et al. Antiemesis[J]. J Natl Compr Canc Netw,2007,5(1):12-33.
[2]
Richardson J L, Marks G, Levine A .The influence of symptoms of disease and side effects of treatment on compliance with cancer therapy[J]. J Clin Oncol,1988,6(11):1746-1752.
[3]
Bloechl-Daum B, Deuson R R, Mavros P, et al.Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment[J].J Clin Oncol,2006,24(27):4472-4478.
[4]
Martin A R, Pearson J D, Cai B, et al . Assessing the impact of chemotherapy-induced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall[J]. Support Care Cancer,2003,11:522-527.
Saito M,Aogi K,Sekine L,et al.Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial[J]. Lancet Oncol,2009,10(2):115-124.
[7]
Cubeddu L X. Serotonin mechanisms in chemotherapy- induced emesis in cancer patients[J].Oncology,1996, 1:18-25 .
[8]
Wolf H. Preclinical and clinical pharmacology of the 5- HT3 receptor antagonists[J].Scand J Rheumatol Suppl,2000,113:37-45.
Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference[J]. Ann Oncol, 2010,21(5):232-243.
[11]
Basch E, Prestrud A A, Hesketh P J, et al. Antiemetic American Society Clinical Oncology clinical practice guideline update[J].J Clin Oncol, 2011,29:4189-4198.
[12]
NCCN Clinical Practice Guidelines in Oncology version 1 2014. Antiemesis[M]. National Comprehensive Cancer Network (NCCN),2014.
[13]
Warr D G,Grunberg S M,Gralla R J, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea andvomiting:Pooled data from 2 randomised, double-blind, placebo controlled trials[J].Eur J Cancer,2013,41(9):1278-1285.
2016, Vol. 27 
